{"product_id":"hind-five-forces","title":"(HIND) Vyome Holdings, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Vyome Holdings, Inc. Porter's Five Forces Analysis helps you understand the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. This page already shows a real preview of the report content, so you can review it before buying. Get the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CRO and CMO dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVyome Holdings, Inc. depends on CROs and CMOs for studies and GMP supply, so suppliers can push hard when they have niche tech, FDA-ready quality systems, or tight capacity. In 2025, pharma outsourcing stayed structurally high, with CRO\/CMO demand still above pre-2020 levels. Switching vendors is slow because validation, tech transfer, and batch-release checks can add months and raise cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarce clinical-grade materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScarce clinical-grade materials give suppliers real leverage for Vyome Holdings, Inc., since immuno-inflammatory and rare disease programs can depend on niche reagents, APIs, and assay inputs with few qualified sources. That can push prices up, limit trial flexibility, and turn a single shipment delay into weeks of lost time and higher cash burn, especially when each late clinical month can add hundreds of thousands of dollars in spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-quality service providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApproved labs, safety-monitoring firms, and GxP-compliant partners have strong bargaining power at Vyome Holdings, Inc. because a single compliance miss can stop an IND, and FDA review can take 30 days before a clinical start. When timelines are tight, these vendors can demand higher fees and stricter terms because the company has little room to switch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific talent concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific talent concentration gives suppliers real leverage: experienced clinical, regulatory, and translational experts are scarce, and Vyome Holdings, Inc. competes with biotech, pharma, and CROs for the same small pool. The U.S. BLS says life, physical, and social science jobs will grow 8% from 2023 to 2033, but that still won’t close the shortage in senior drug-development roles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScarce senior biotech talent\u003c\/li\u003e\n\u003cli\u003eHigher pay raises labor power\u003c\/li\u003e\n\u003cli\u003eRetention risk lifts costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and licensing holders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVyome Holdings, Inc. can face strong supplier power if it relies on in-licensed technologies or third-party patents, because licensors can set upfront fees, milestones, and royalties. In biotech, core patent protection often runs 20 years from filing, so control of key IP can shape deal economics.\u003c\/p\u003e\n\u003cp\u003eIn early development, access to a unique platform can matter more than price, since losing it can delay programs or block them. That makes strategically scarce IP holders harder to replace, which raises bargaining power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFees and milestones can lift costs\u003c\/li\u003e\n\u003cli\u003eUnique IP raises switching risk\u003c\/li\u003e\n\u003cli\u003eEarly-stage access often beats price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyome Faces Tight Supplier Power as CRO and CMO Capacity Stays Constrained\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVyome Holdings, Inc. faces high supplier power because CROs, CMOs, and GMP labs are still capacity tight, and switching can take months for tech transfer and validation. Scarce reagents, APIs, and assay inputs give niche vendors pricing power, while late-stage clinical delays can add hundreds of thousands of dollars in burn. In biotech, one compliance miss can stop an IND, so qualified partners can demand higher fees.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO demand\u003c\/td\u003e\n\u003ctd\u003eStill above pre-2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVendor switch time\u003c\/td\u003e\n\u003ctd\u003eMonths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND review\u003c\/td\u003e\n\u003ctd\u003e30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate clinical cost\u003c\/td\u003e\n\u003ctd\u003eHundreds of thousands per month\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTailored Porter’s Five Forces analysis of Vyome Holdings, Inc., highlighting competition, supplier and buyer power, substitutes, and entry risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Vyome Holdings’ key competitive pressures in one clear view—saving time on strategic analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Vyome Holdings, Inc., helping decision-makers verify key claims and update assumptions quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow current direct customer power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVyome Holdings, Inc. is still clinical-stage, so it likely has no commercial product sales yet; that keeps direct customer bargaining power low today. With no marketed therapy, end users cannot press for price cuts or contract changes the way they can with approved drugs. The real pressure starts after launch, when payers, providers, and patients can influence access, pricing, and uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealth insurers and government payers can make or break Vyome Holdings, Inc. future launches. In the US, CMS covers about 66 million Medicare beneficiaries, and 2025 Part D changes pushed stronger price and value scrutiny, so payers now expect clear clinical benefit, safety data, and cost savings. Without favorable reimbursement, even differentiated therapies can stall at scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician prescribing influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDoctors act as gatekeepers in immuno-inflammatory and rare disease care. In the U.S., a rare disease affects fewer than 200,000 people, and about 95% still lack an FDA-approved treatment, so prescribing choice often drives access. \u003c\/p\u003e\n\u003cp\u003eThat keeps physician power high for Vyome Holdings, Inc., because uptake depends on proven efficacy, safety, and easy use. If competing therapies are already trusted, doctors can slow switching and limit launch traction. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient advocacy and switching limits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn rare diseases, patients and advocacy groups are often very informed and selective; about 300 million people live with 7,000+ rare diseases, and roughly 95% still lack approved treatments. That lifts bargaining power on evidence and access, but if Vyome Holdings, Inc. offers clear clinical benefit, price sensitivity can drop fast.\u003c\/p\u003e\n\u003cp\u003eSwitching is also limited by diagnosis delays, specialist care, and narrow treatment options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh patient scrutiny.\u003c\/li\u003e\n\u003cli\u003eLow switching in severe need.\u003c\/li\u003e\n\u003cli\u003eBenefit beats price.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotential partnering customer leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf Vyome Holdings, Inc. pursues licensing or co-development deals, large pharma partners can hold strong leverage because they bring capital, sales reach, and shared risk. That can force Vyome Holdings, Inc. to accept lower upfront fees, slimmer milestones, or weaker royalty rates. The result is margin pressure on future collaborations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge pharma sets deal terms\u003c\/li\u003e\n\u003cli\u003eCapital and reach boost leverage\u003c\/li\u003e\n\u003cli\u003eRoyalties and milestones may shrink\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyome Faces Rising Payer and Patient Pressure as Access Tightens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVyome Holdings, Inc. faces low customer power before launch, but payer and physician power rises fast once pricing and access matter. In the U.S., CMS covers about 66 million Medicare lives, and 2025 Part D rules tightened price and value scrutiny. Rare-disease patients also push hard on evidence, since about 95% of 7,000+ rare diseases still lack approved treatment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eForce\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e66M Medicare lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolicy\u003c\/td\u003e\n\u003ctd\u003e2025 Part D scrutiny\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e95% untreated rare diseases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVyome Holdings, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Vyome Holdings, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no placeholders, no edits needed. The document is fully written and professionally formatted, so what you see here is the same file you’ll download instantly. It’s ready for immediate use in research, strategy, or investment analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded immunology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe immuno-inflammatory space is crowded, with large drugmakers like AbbVie and Johnson \u0026amp; Johnson, plus many biotechs, chasing the same pathways. Big rivals already have marketed blockbusters and deeper cash, while many peers sit in late-stage trials. That raises the bar for Vyome Holdings, Inc. to show a clear clinical edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease niche competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare disease markets are small, but they can still draw intense rivalry because orphan drugs get 7 years of U.S. exclusivity and premium pricing. More than 7,000 rare diseases affect about 300 million people worldwide, so many biotechs chase the same biology in the same narrow pool. In this niche, speed, clean clinical data, and a sharp FDA strategy often decide who wins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBig pharma and biotech overlap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBig pharma and biotech often clash in the same drug spaces, and the scale gap is huge: in 2025, top drugmakers like Pfizer and Merck each posted tens of billions in annual revenue, while many biotechs still rely on one or two lead assets.\u003c\/p\u003e\n\u003cp\u003eThat gives big pharma more cash, sales reach, and trial capacity, so smaller firms such as Vyome Holdings, Inc. must show strong clinical data fast.\u003c\/p\u003e\n\u003cp\u003eBiotech can move quicker, but the market is less forgiving when results slip or timelines stretch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical milestone race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn biotech, clinical milestone race is the rivalry driver: the first proof-of-concept readout can rerate a company fast. Industry data shows only about 1 in 10 drug candidates reaches approval, so Phase 2 efficacy and safety data can make or break investor interest. Delays can cut partner leverage and weaken Vyome Holdings, Inc.'s position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst proof-of-concept wins attention.\u003c\/li\u003e\n\u003cli\u003eCleaner safety data lifts valuation.\u003c\/li\u003e\n\u003cli\u003eDelays can hurt deal power fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and platform competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn Vyome Holdings, Inc.'s space, rivals compete on data, but also on IP coverage and exclusivity. A strong patent estate can block copycats, extend partnering power, and raise switching costs; weak IP can let a similar program move fast once proof of concept is visible.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents can slow imitation.\u003c\/li\u003e\n\u003cli\u003eExclusivity improves deal leverage.\u003c\/li\u003e\n\u003cli\u003eWeak IP invites fast copycats.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSo rivalry is not just about clinical results; it is also about who can defend the platform longest and monetize it first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyome Faces Fierce Rivalry in Crowded Rare-Disease and Inflammation Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because Vyome Holdings, Inc. faces big drugmakers with 2025 revenue in the tens of billions, plus many biotechs chasing the same inflammatory and rare-disease targets. In rare disease, the pool is small but crowded: over 7,000 diseases affect about 300 million people worldwide, and 7 years of U.S. orphan exclusivity still draws fast-moving rivals.\u003c\/p\u003e\n\u003cp\u003eThe edge goes to the company with the first clean Phase 2 data, strong patent coverage, and speed to FDA action. Since only about 1 in 10 drug candidates reaches approval, delays can quickly weaken pricing power and partner leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRivalry driver\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma scale\u003c\/td\u003e\n\u003ctd\u003e2025 revenue: Pfizer, Merck, tens of billions\u003c\/td\u003e\n\u003ctd\u003eMore cash and trial firepower\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease crowding\u003c\/td\u003e\n\u003ctd\u003e7,000+ diseases, 300M people\u003c\/td\u003e\n\u003ctd\u003eMany firms chase the same biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment risk\u003c\/td\u003e\n\u003ctd\u003e~10% approval rate\u003c\/td\u003e\n\u003ctd\u003eEarly data can rerate fast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting standard-of-care therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and physicians already rely on standard-of-care options like corticosteroids, methotrexate, and biologics, so these are direct substitutes for Vyome Holdings, Inc. In 2025, Humira still generated about $8.7 billion in net sales, showing how entrenched familiar therapies remain. A new Vyome product must beat them on efficacy, safety, or ease of use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics and biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApproved biologics already dominate many inflammatory diseases, and by mid-2025 the FDA had cleared 60+ biosimilars, with Humira biosimilars driving sharp price pressure in the U.S. That lowers current-care costs and raises the bar for Vyome Holdings, Inc. pipeline assets. Vyome needs a clear clinical edge on efficacy, safety, or dosing to win share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOff-label and symptomatic care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOff-label drugs, topical steroids, and supportive care can keep symptoms manageable when targeted options are scarce, which lowers near-term demand for a new therapy. In practice, if existing symptom control is acceptable, doctors have less pressure to switch. That makes the substitute threat higher in conditions where symptom relief is easy to get and cheap to keep using.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging modality alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGene therapy and cell therapy are real substitutes in rare disease, and they keep pulling capital away from older drug plays. By 2025, the FDA had cleared more than 30 cell and gene therapies, so physician and payer attention is already shifting.\u003c\/p\u003e\n\u003cp\u003eNext-generation immunology platforms also widen the field, since they can target the same patient pools with different science and faster trial paths. That makes Vyome Holdings, Inc. face not just direct drug rivals, but also platform-backed capital and partner competition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eMore approved therapies raise substitution pressure.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFunding now follows platform depth, not only drugs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRare-disease partners can switch to newer modalities.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-drug management options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-drug options can trim Vyome Holdings, Inc. medication demand in inflammatory disease, especially when diet, monitoring, surgery, or devices cut symptoms at lower cost. In rare genetic disorders, though, they rarely replace drug therapy because the root cause stays untreated.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigher threat in common inflammatory care.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLower threat in rare genetic disease.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBest when burden falls without drugs.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSo the threat of substitutes is moderate and depends on how much these options reduce flare-ups, procedures, and total care cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstitute Pressure on Vyome Remains Moderate in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Vyome Holdings, Inc. is moderate: standard drugs, biosimilars, and non-drug care already cap pricing power. In 2025, Humira still delivered about $8.7 billion in net sales, and 60+ FDA-cleared biosimilars increased price pressure. New therapies must win on efficacy, safety, or dosing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003ePressure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumira\u003c\/td\u003e\n\u003ctd\u003e$8.7B sales\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e60+ cleared\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupportive care\u003c\/td\u003e\n\u003ctd\u003eLow-cost use\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Vyome Holdings, Inc., high regulatory barriers make entry hard because drug programs often take 10 to 15 years and can cost over $2 billion before launch. The FDA process needs strong preclinical, clinical, and safety proof, and only about 1 in 10 drugs entering Phase I reach approval. That long timeline and high failure risk push many would-be entrants out.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity and burn risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunching a biotech program takes heavy cash before any revenue: CRO, GMP manufacturing, FDA\/EMA compliance, and talent can run into tens of millions of dollars. In 2025, many small biotech IPOs still raised under $20 million, which is often not enough for a full clinical path. That burn risk makes new entrants rare, so the barrier to scale is high for Vyome Holdings, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and exclusivity obstacles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Vyome Holdings, Inc., patent walls and FDA exclusivity raise the bar for new entrants: U.S. patents last 20 years from filing, and new drugs can get 5 years of NCE exclusivity, 7 years for orphan drugs, or 12 years for biologics. That can block or delay rival programs, especially in niche therapies where one protected asset can define the market. Strong IP means copycats often need years, not months, to catch up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific and operational complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific and operational complexity keeps entry barriers high for Vyome Holdings, Inc. New drug work needs deep translational science, tight trial design, and GxP quality systems, while only about 1 in 10 drug candidates reaches approval. Building that stack can take 10 to 15 years and often costs more than $2 billion, so small entrants usually lack the speed and controls to compete.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNeeds rare scientific depth\u003c\/li\u003e\n\u003cli\u003eTrial errors are costly\u003c\/li\u003e\n\u003cli\u003eQuality systems take years\u003c\/li\u003e\n\u003cli\u003eHigh cost delays entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess to partners and credibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to trusted partners is a real barrier for Vyome Holdings, Inc. New entrants must win over investigators, regulators, investors, and payers before they can even secure CROs, manufacturers, or licensing deals. In biotech, that trust usually comes from a track record, so established or well-backed firms start with a clear edge.\u003c\/p\u003e\n\u003cp\u003eWithout proof of execution, partner diligence can stall and raise costs fast. That makes entry harder for smaller firms, while stronger balance sheets and prior clinical wins improve access to capital and deal flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrust drives partner access.\u003c\/li\u003e\n\u003cli\u003eTrack record lowers diligence risk.\u003c\/li\u003e\n\u003cli\u003eWeak backing slows CRO deals.\u003c\/li\u003e\n\u003cli\u003eEstablished firms hold the edge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyome’s Entry Barriers: Time, Cost, and Patent Walls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor Vyome Holdings, Inc., new entrants face a steep wall: drug development often takes 10 to 15 years, costs over $2 billion, and only about 1 in 10 Phase I drugs reach approval. In 2025, many small biotech IPOs raised under $20 million, which rarely covers a full clinical path. Patents and FDA exclusivity further slow copycats and protect first movers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment time\u003c\/td\u003e\n\u003ctd\u003e10-15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase I success\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmall biotech IPOs\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$20M in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234455691529,"sku":"hind-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/hind-five-forces.webp?v=1785720873","url":"https:\/\/dcfanalyst.com\/products\/hind-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}